Scholarlink

Background <p>Evidence on the drug effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on mortality in patients with diabetic kidney disease (DKD) remains limited. We analyzed patients with DKD newly prescribed SGLT2is using large-scale Asian real-world data.</p> Methods <p>We utilized commercially available databases provided by DeSC Healthcare, Inc., between 2014 and 2023. All-cause mortality was compared across five pairs of new users of SGLT2is—canagliflozin, empagliflozin, ipragliflozin, luseogliflozin, or tofogliflozin—each versus dapagliflozin, using a target trial emulation framework with propensity score matching.</p> Results <p>Among 12,308 patients with DKD, 1,553 new users of canagliflozin, 2,948 of empagliflozin, 1,672 of ipragliflozin, 931 of luseogliflozin, and 955 of tofogliflozin were matched 1:1 with corresponding new users of dapagliflozin. The mean age of participants ranged from 72.2 to 75.4&#xa0;years, and 67.4–72.2% were men. During a median follow-up period of 1.12–1.96&#xa0;years, the incidence of all-cause mortality among new users of SGLT2 inhibitors ranged from 32.3 to 46.2 for dapagliflozin, and was 28.8 for canagliflozin, 38.8 for empagliflozin, 33.4 for ipragliflozin, 33.8 for luseogliflozin, and 25.7 for tofogliflozin, per 1,000 person-years. Both the cumulative incidence and hazard ratios for all-cause mortality were comparable among new users of each SGLT2i compared with dapagliflozin (all log-rank <i>P</i> &gt; 0.05; 95% CIs included 1).</p> Conclusions <p>Comparable effects of SGLT2is on all-cause mortality risk were observed in patients with DKD using the Asian real-world data. This apparent class effect on all-cause mortality suggests that different agents may confer comparable short-term mortality benefits when selected according to patient characteristics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of individual sodium-glucose cotransporter-2 inhibitors on all-cause mortality in patients with diabetic kidney disease

  • 期刊论文

  • 发表日期：

    2026年4月11日

查看全文
  • Hiroki Nobayashi,
  • Michihiro Satoh,
  • Takuo Hirose,
  • Shingo Nakayama,
  • Yutaro Iwabe,
  • Takahito Yagihashi,
  • Hideaki Hashimoto,
  • Takahisa Murakami,
  • Kouji Okada,
  • Takefumi Mori,
  • Hirohito Metoki

摘要

Background

Evidence on the drug effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on mortality in patients with diabetic kidney disease (DKD) remains limited. We analyzed patients with DKD newly prescribed SGLT2is using large-scale Asian real-world data.

Methods

We utilized commercially available databases provided by DeSC Healthcare, Inc., between 2014 and 2023. All-cause mortality was compared across five pairs of new users of SGLT2is—canagliflozin, empagliflozin, ipragliflozin, luseogliflozin, or tofogliflozin—each versus dapagliflozin, using a target trial emulation framework with propensity score matching.

Results

Among 12,308 patients with DKD, 1,553 new users of canagliflozin, 2,948 of empagliflozin, 1,672 of ipragliflozin, 931 of luseogliflozin, and 955 of tofogliflozin were matched 1:1 with corresponding new users of dapagliflozin. The mean age of participants ranged from 72.2 to 75.4 years, and 67.4–72.2% were men. During a median follow-up period of 1.12–1.96 years, the incidence of all-cause mortality among new users of SGLT2 inhibitors ranged from 32.3 to 46.2 for dapagliflozin, and was 28.8 for canagliflozin, 38.8 for empagliflozin, 33.4 for ipragliflozin, 33.8 for luseogliflozin, and 25.7 for tofogliflozin, per 1,000 person-years. Both the cumulative incidence and hazard ratios for all-cause mortality were comparable among new users of each SGLT2i compared with dapagliflozin (all log-rank P > 0.05; 95% CIs included 1).

Conclusions

Comparable effects of SGLT2is on all-cause mortality risk were observed in patients with DKD using the Asian real-world data. This apparent class effect on all-cause mortality suggests that different agents may confer comparable short-term mortality benefits when selected according to patient characteristics.